Columvi combined with gemcitabine and oxaliplatin dramatically extends survival in people with relapsed or refractory diffuse large B-cell lymphoma
Expands bioprocessing footprint across Asia
This collaboration sets the stage for WuXi Biologics’ first integrated CRDMO center in the region
Biocon will acquire all of Viatris’ convertible preferred equity in Biocon Biologics for $400 million in cash and $415 million in newly issued Biocon shares
The study met its primary endpoint and all 11 secondary efficacy endpoints
It's a development that marks a potential breakthrough for people living with the rare and debilitating disease Duchenne muscular dystrophy (DMD)
Freenome expects the combined company to receive approximately $330 million in proceeds at closing
Captured microbes are then neutralized on engineered microbicidal surfaces
The launch of the study was on the occasion of the International Day of Persons with Disabilities
76 of 180 long COVID-associated genes also linked to ME
Subscribe To Our Newsletter & Stay Updated
